Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: A systematic review and meta-analysis approach of individual drugs

Arthritis Care and Research

Volumn 66, Issue 7, 2014, Pages 1073-1084

  Simonini, Gabriele ^a   Druce, Katie ^b   Cimaz, Rolando ^a   Macfarlane, Gary J ^b   Jones, Gareth T ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALOPECIA; AUTOIMMUNE UVEITIS; CHILD; CHILDHOOD DISEASE; COCHRANE LIBRARY; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EMBASE; EVIDENCE BASED MEDICINE; FATIGUE; HERPES SIMPLEX KERATITIS; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE REACTION; LEUKOPENIA; MEDLINE; META ANALYSIS; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PAIN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DETACHMENT; RETINA MACULA EDEMA; REVIEW; SKIN MANIFESTATION; STEROID THERAPY; SYSTEMATIC REVIEW; TINEA VERSICOLOR; TREATMENT RESPONSE; VITREOUS HEMORRHAGE;

ANTIRHEUMATIC AGENTS; CHILD; CHRONIC DISEASE; HUMANS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; VISUAL ACUITY;

EID: 84903449205     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22214     Document Type: Review

References (48)

1. Benezra D, Cohen E, Maftizir G,. Uveitis in children and adolescents. Br J Ophthalmol 2005; 89: 44-8.
2. Zierhut M, Doycheva D, Biester S, Stubiger N, Kummerle-Descher J, Deuter C,. Therapy of uveitis in children. Int Ophthalmol Clin 2008; 48: 131-52.
3. Sharma SM, Dick AD, Ramanan AV,. Non-infectious pediatric uveitis: an update on immunomodulatory management. Paediatr Drugs 2009; 11: 229-41.
4. Simonini G, Cantarini L, Bresci C, Lorusso M, Galeazzi M, Cimaz R,. Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmun Rev 2010; 9: 674-83.
5. Imrie FR, Dick AD,. Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007; 18: 481-6.
6. Jabs DA, Nussemblatt RB, Rosembaum JT, and the Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the first international workshop. Am J Ophthalmol 2005; 140: 509-16.
7. Jabs DA,. Improving the reporting of clinical case series. Am J Ophthalmol 2005; 139: 900-5.
8. Simonini G, Taddio A, Cattalini M, Caputo R, De Libero C, Naviglio S, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken) 2011; 63: 612-8.
9. Gallagher M, Quinones K, Cervantes-Castaneda RA, Yilmaz T, Foster CS,. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 2007; 91: 1341-4.
10. Tynjala P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K,. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007; 66: 548-50.
11. Sen ES, Sharma S, Hinchcliffe A, Dick AD, Ramanan AV,. Use of adalimumab in refractory non-infectious childhood chronic uveitis. Efficacy in ocular disease: a case cohort interventional study. Rheumatology (Oxford) 2012; 51: 2199-03.
12. Sukumaran S, Marzan K, Shaham B, Reiff A,. High dose infliximab in the treatment of refractory uveitis: does dose matter? ISRN Rheumatol 2012; 2012: 765380.
13. Khalifa YM, Bailony MR, Acharya NR,. Treatment of pediatric Vogt-Koyanagi-Harada syndrome with infliximab. Ocul Immunol Inflamm 2010; 18: 218-22.
14. Julian K, Terrada C, Quartier P, Lehoang P, Bodaghi B,. Uveitis related to juvenile idiopathic arthritis: familial cases and possible genetic implication in the pathogenesis. Ocul Immunol Inflamm 2010; 18: 172-7.
15. Dhingra N, Morgan J, Dick AD,. Switching biologic agents for uveitis. Eye (Lond) 2009; 23: 1868-70.
16. Cantarini L, Tinazzi I, Caramaschi P, Bellisai F, Brogna A, Galeazzi M,. Safety and efficacy of etanercept in children with juvenile-onset Behcets disease. Int J Immunopathol Pharmacol 2009; 22: 551-5.
17. Tugal-Tutkun I, Ayranci O, Kasapcopur O, Kir N,. Retrospective analysis of children with uveitis treated with infliximab. J AAPOS 2008; 12: 611-3.
18. Ardoin SP, Kredich D, Rabinovich E, Schanberg LE, Jaffe GJ,. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol 2007; 144: 844-9.
19. Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007; 91: 319-24.
20. Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS,. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007; 125: 895-900.
21. Kahn P, Weiss M, Imundo LF, Levy DM,. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006; 113: 860-4.
22. Vazquez-Cobian LB, Flynn T, Lehman TJ,. Adalimumab therapy for childhood uveitis. J Pediatr 2006; 149: 572-5.
23. Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS,. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 2006; 113: 308-14.
24. Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A,. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease. Int Ophthalmol 2005; 26: 83-92.
25. Richards JC, Tay-Kearney ML, Murray K, Manners P,. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Experiment Ophthalmol 2005; 33: 461-8.
26. Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001; 45: 252-7.
27. Suhler EB, Smith JR, Giles TR, Lauer AK, Wertheim MS, Kurz DE, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 2009; 127: 819-22.
28. Simonini G, Zannin ME, Caputo R, Falcini F, de Martino M, Zulian F, et al. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Rheumatology (Oxford) 2008; 47: 1510-4.
29. Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001; 44: 1411-5.
30. Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005; 53: 18-23.
31. Smith JA, Mackensen F, Sen HN, Leigh JF, Watkins AS, Pyatetsky D, et al. Epidemiology and course of disease in childhood uveitis. Ophthalmology 2009; 116: 1544-51.
32. Sharma SM, Ramanan AV, Riley P, Dick AD,. Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease. Ann Rheum Dis 2007; 66: 840-1.
33. Kramer M, Amer R, Mukamel M, Snir M, Jaouni T, Friling R,. Uveitis in juvenile Behçet's disease: clinical course and visual outcome compared with adult patients. Eye (Lond) 2009; 23: 2034-41.
34. Asproudis I, Felekis T, Tsanou E, Gorezis S, Karali E, Alfantaki S, et al. Juvenile idiopathic arthritis-associated uveitis: data from a region in Western Greece. Clin Ophthalmol 2010; 4: 343-7.
35. Kesen MR, Goldstein DA, Tessler HH,. Uveitis associated with paediatric Behçet disease in the American Midwest. Am J Ophthalmol 2008; 146: 819-27.
36. Keino H, Okada AO, Watanabe T, Taki W,. Decreased ocular inflammation attacks and background retinal and disc vascular leakage in patients with Behçet's disease on infliximab therapy. Br J Ophthalmol 2011; 95: 1245-50.
37. Galor A, Perez VL, Hammel JP, Lowder CY,. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006; 113: 2317-23.
38. Diaz-Llopis M, Salom D, Garcia-de-Vicuna C, Cordero-Coma M, Ortega G, Ortego N, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 2012; 119: 1575-81.
39. Kotaniemi K, Saila H, Kautiainen H,. Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol 2011; 5: 1425-9.
40. Tynjala P, Kotaniemi K, Lindahl P, Latva K, Aalto K, Honkanen V, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 2008; 47: 339-44.
41. Marvillet I, Terrada C, Quartier P, Quoc EB, Bodaghi B, Prieur AM,. Ocular threat in juvenile idiopathic arthritis. Joint Bone Spine 2009; 76: 383-8.
42. Southwood TR, Foster HE, Davidson JE, Hyrich KL, Cotter CB, Wedderburn LR, et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford) 2011; 50: 189-95.
43. Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63: 1638-44.
44. Foeldvari I, Nielsen S, Kummerle-Deschner J, Espada G, Horneff G, Bica B, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007; 34: 1146-50.
45. Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 2006; 45: 982-9.
46. Schmeling H, Horneff G,. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 2005; 44: 1008-11.
47. Simonini G, Paudyal P, Gareth T, Jones GT, Cimaz R, Macfarlane GJ,. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology (Oxford) 2013; 52: 825-31.
48. Phillips B, Ball C, Badenoch D, Straus S, Haynes B, Dawes M,. Oxford Centre for Evidence-based Medicine Levels of Evidence. BJU Int 2009; 104: 1825.